The well‐characterized ability of PDE5 inhibitors such as tadalafil to increase blood flow by way of arterial vasodilatation in the setting of pulmonary hypertension has led to the hypothesis that these same PDE5 inhibitors may also be useful in placental insufficiency‐induced FGR by increasing maternal blood flow to the uterus (Rotella, 2002). This evidence concerns the gene PDE5A and placental insufficiency.